The effects of age and resveratrol on the hypoxic preconditioning protection against hypoxia-reperfusion injury: Studies in rat hearts and human cardiomyocytes

European Journal of Cardio-thoracic Surgery

Volumn 48, Issue 3, 2015, Pages 375-381

  Zheng, Hong ^a   Guo, Hai ^a   Hong, Yi ^a   Zheng, Fen ^a   Wang, Jiang ^a  

^a XINJIANG MEDICAL UNIVERSITY   (China)

Author keywords

HIF 1; Hypoxia reperfusion injury; Myocardial ischaemic preconditioning; Resveratrol; SIRT1

Indexed keywords

LACTATE DEHYDROGENASE; RESVERATROL; CARDIOTONIC AGENT; STILBENE DERIVATIVE;

ADULT; AGE; AGED; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL DAMAGE; CELL SURVIVAL; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG EFFECT; GROUPS BY AGE; HEART LEFT VENTRICLE PRESSURE; HEART MUSCLE CELL; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HEART RATE; HEART VENTRICLE FUNCTION; HUMAN; HUMAN CELL; ISCHEMIC PRECONDITIONING; ISOLATED HEART; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; REPERFUSION INJURY; ANIMAL; CARDIAC MUSCLE CELL; CELL CULTURE; DRUG EFFECTS; HEART INFARCTION PREVENTION; MYOCARDIAL REPERFUSION INJURY; PROCEDURES;

AGE FACTORS; ANIMALS; CARDIOTONIC AGENTS; CELLS, CULTURED; HEART RATE; HUMANS; ISCHEMIC PRECONDITIONING, MYOCARDIAL; MALE; MYOCARDIAL REPERFUSION INJURY; MYOCYTES, CARDIAC; RATS; STILBENES; VENTRICULAR FUNCTION;

EID: 84934316008     PISSN: 10107940     EISSN: 1873734X     Source Type: Journal    
DOI: 10.1093/ejcts/ezu494     Document Type: Article

References (14)

1. Jennings RB. Historical perspective on the pathology of myocardial ischemia/reperfusion injury. Circ Res 2013;113:428-38.
2. Boengler K, Schulz R, Heusch G. Loss of cardioprotection with ageing. Cardiovasc Res 2009;83:247-61.
3. Adam T, Sharp S, Opie LH, Lecour S. Loss of cardioprotection with ischemic preconditioning in aging hearts: role of sirtuin 1? J Cardiovasc Pharmacol Ther 2013;18:46-53.
4. Clark D, Tuor UI, Thompson R, Institoris A, Kulynych A, Zhang X et al. Protection against recurrent stroke with resveratrol: endothelial protection. PLoS One 2012;7:e47792.
5. Borra MT, Smith BC, Denu JM. Mechanism of human SIRT1 activation by resveratrol. J Biol Chem 2005;280:17187-95.
6. Pervaiz S. Resveratrol: from grapevines to mammalian biology. FASEB J 2003;17:1975-19985.
7. Bell RM, Mocanu MM, Yellon DM. Retrograde heart perfusion: the Langendorff technique of isolated heart perfusion. J Mol Cell Cardiol 2011;50:940-50.
8. Laemmle A, Lechleiter A, Roh V, Schwarz C, Portmann S, Furer C et al. Inhibition of SIRT1 impairs the accumulation and transcriptional activity of HIF-1α protein under hypoxic conditions. PLoS ONE 2012;7:e33433.
9. Bartling B, Friedrich I, Silber RE, Simm A. Ischemic preconditioning is not cardioprotective in senescent human myocardium. Ann Thorac Surg 2013;76:105-11.
10. Ventura-Clapier R. Potentiating exercise training with resveratrol. J Physiol 2012;590:3215-6.
11. Andersen A, Povlsen JA, Botker HE, Nielsen-Kudsk JE. Ischemic preconditioning reduces right ventricular infarct size through opening of mitochondrial potassium channels. Cardiology 2012;123:177-80.
12. Zhang X, Xiao Z, Yao J, Zhao G, Fa X, Niu J. Participation of protein kinase C in the activation of Nrf2 signaling by ischemic preconditioning in the isolated rabbit heart. Mol Cell Biochem 2013;372:169-79.
13. Shinmura K, Tamaki K, Bolli R. Impact of 6-mo caloric restriction on myocardial ischemic tolerance: possible involvement of nitric oxidedependent increase in nuclear Sirt1. Am J Physiol Heart Circ Physiol 2008; 295:H2348-55.
14. Alcendor RR, Kirshenbaum LA, Imai S, Vatner SF, Sadoshima J. Silent information regulator 2alpha, a longevity factor and class III histone deacetylase, is an essential endogenous apoptosis inhibitor in cardiac myocytes. Circ Res 2004;95:971-80.